Halozyme Therapeutics Stock Price Prediction
| HALO Stock | USD 57.99 0.51 0.87% |
Momentum 69
Buy Stretched
Oversold | Overbought |
Quarterly Earnings Growth 0.623 | EPS Estimate Next Quarter 0.972 | EPS Estimate Current Year 4.9278 | EPS Estimate Next Year 6.4451 | Wall Street Target Price 66.1111 |
Using Halozyme Therapeutics hype-based prediction, you can estimate the value of Halozyme Therapeutics from the perspective of Halozyme Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Halozyme Therapeutics using Halozyme Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Halozyme using crowd psychology based on the activity and movement of Halozyme Therapeutics' stock price.
Halozyme Therapeutics Short Interest
An investor who is long Halozyme Therapeutics may also wish to track short interest. As short interest increases, investors should be becoming more worried about Halozyme Therapeutics and may potentially protect profits, hedge Halozyme Therapeutics with its derivative instruments, or be ready for some potential downside.
200 Day MA 53.0932 | Short Percent 0.0963 | Short Ratio 6.59 | Shares Short Prior Month 9.4 M | 50 Day MA 53.0408 |
Halozyme Therapeutics Hype to Price Pattern
Investor biases related to Halozyme Therapeutics' public news can be used to forecast risks associated with an investment in Halozyme. The trend in average sentiment can be used to explain how an investor holding Halozyme can time the market purely based on public headlines and social activities around Halozyme Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Halozyme Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Halozyme Therapeutics.
Halozyme Therapeutics Implied Volatility | 0.56 |
Halozyme Therapeutics' implied volatility exposes the market's sentiment of Halozyme Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Halozyme Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Halozyme Therapeutics stock will not fluctuate a lot when Halozyme Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Halozyme Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Halozyme because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Halozyme Therapeutics after-hype prediction price | USD 58.54 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Halozyme contract
Based on the Rule 16, the options market is currently suggesting that Halozyme Therapeutics will have an average daily up or down price movement of about 0.035% per day over the life of the 2025-04-17 option contract. With Halozyme Therapeutics trading at USD 57.99, that is roughly USD 0.0203 . If you think that the market is fully incorporating Halozyme Therapeutics' daily price movement you should consider acquiring Halozyme Therapeutics options at the current volatility level of 0.56%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Halozyme |
Halozyme Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Halozyme Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Halozyme Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Halozyme Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Halozyme Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Halozyme Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Halozyme Therapeutics' historical news coverage. Halozyme Therapeutics' after-hype downside and upside margins for the prediction period are 57.06 and 60.02, respectively. We have considered Halozyme Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Halozyme Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of Halozyme Therapeutics is based on 3 months time horizon.
Halozyme Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Halozyme Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Halozyme Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Halozyme Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.32 | 1.47 | 0.04 | 0.15 | 7 Events / Month | 12 Events / Month | In about 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
57.99 | 58.54 | 0.07 |
|
Halozyme Therapeutics Hype Timeline
Halozyme Therapeutics is currently traded for 57.99. The entity has historical hype elasticity of 0.04, and average elasticity to hype of competition of 0.15. Halozyme is expected to increase in value after the next headline, with the price projected to jump to 58.54 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 0.07%, whereas the daily expected return is currently at 0.32%. The volatility of related hype on Halozyme Therapeutics is about 305.04%, with the expected price after the next announcement by competition of 58.14. The company reported the previous year's revenue of 1.02 B. Net Income was 444.09 M with profit before overhead, payroll, taxes, and interest of 776.86 M. Given the investment horizon of 90 days the next expected press release will be in about 7 days. Check out Halozyme Therapeutics Basic Forecasting Models to cross-verify your projections.Halozyme Therapeutics Related Hype Analysis
Having access to credible news sources related to Halozyme Therapeutics' direct competition is more important than ever and may enhance your ability to predict Halozyme Therapeutics' future price movements. Getting to know how Halozyme Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Halozyme Therapeutics may potentially react to the hype associated with one of its peers.
Halozyme Therapeutics Additional Predictive Modules
Most predictive techniques to examine Halozyme price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Halozyme using various technical indicators. When you analyze Halozyme charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Halozyme Therapeutics Predictive Indicators
The successful prediction of Halozyme Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Halozyme Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Halozyme Therapeutics based on analysis of Halozyme Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Halozyme Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Halozyme Therapeutics's related companies. | 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 7.87 | 16.28 | 15.55 | 16.33 | Days Of Inventory On Hand | 262.34 | 242.12 | 324.8 | 574.15 |
Story Coverage note for Halozyme Therapeutics
The number of cover stories for Halozyme Therapeutics depends on current market conditions and Halozyme Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Halozyme Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Halozyme Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Halozyme Therapeutics Short Properties
Halozyme Therapeutics' future price predictability will typically decrease when Halozyme Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Halozyme Therapeutics often depends not only on the future outlook of the potential Halozyme Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Halozyme Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 129.4 M | |
| Cash And Short Term Investments | 596.1 M |
Check out Halozyme Therapeutics Basic Forecasting Models to cross-verify your projections. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.623 | Earnings Share 3.43 | Revenue Per Share | Quarterly Revenue Growth 0.295 | Return On Assets |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.